These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29215650)

  • 1. Phenocopies in melanoma-prone families with germ-line CDKN2A mutations.
    Helgadottir H; Olsson H; Tucker MA; Yang XR; Höiom V; Goldstein AM
    Genet Med; 2018 Sep; 20(9):1087-1090. PubMed ID: 29215650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
    Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
    Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.
    Helgadottir H; Höiom V; Tuominen R; Nielsen K; Jönsson G; Olsson H; Hansson J
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27287845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric melanoma in melanoma-prone families.
    Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA
    Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.
    Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V
    J Am Acad Dermatol; 2017 Nov; 77(5):893-901. PubMed ID: 28818438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk.
    Aspinwall LG; Stump TK; Taber JM; Drummond DM; Kohlmann W; Champine M; Leachman SA
    Transl Behav Med; 2018 Jan; 8(1):29-43. PubMed ID: 29385581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway.
    Levin T; Mæhle L
    Fam Cancer; 2017 Apr; 16(2):257-265. PubMed ID: 27804060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers.
    Gironi LC; Colombo E; Pasini B; Giorgione R; Farinelli P; Zottarelli F; Esposto E; Zavattaro E; Allara E; Ogliara P; Betti M; Dianzani I; Savoia P
    Arch Dermatol Res; 2018 Dec; 310(10):769-784. PubMed ID: 30218143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma-specific survival before and after inclusion in a familial melanoma dermatologic surveillance program in CDKN2A mutation carriers and non-carriers.
    Pissa M; Lapins J; Sköldmark C; Helgadottir H
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):284-292. PubMed ID: 36156317
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
    Acta Oncol; 2021 Jul; 60(7):888-896. PubMed ID: 33945383
    [No Abstract]   [Full Text] [Related]  

  • 12. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.
    Taylor NJ; Mitra N; Goldstein AM; Tucker MA; Avril MF; Azizi E; Bergman W; Bishop DT; Bressac-de Paillerets B; Bruno W; Calista D; Cannon-Albright LA; Cuellar F; Cust AE; Demenais F; Elder DE; Gerdes AM; Ghiorzo P; Grazziotin TC; Hansson J; Harland M; Hayward NK; Hocevar M; Höiom V; Ingvar C; Landi MT; Landman G; Larre-Borges A; Leachman SA; Mann GJ; Nagore E; Olsson H; Palmer JM; Perić B; Pjanova D; Pritchard A; Puig S; van der Stoep N; Wadt KAW; Whitaker L; Yang XR; Newton Bishop JA; Gruis NA; Kanetsky PA;
    J Invest Dermatol; 2017 Dec; 137(12):2606-2612. PubMed ID: 28830827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Longitudinal Surveillance on Tumor Thickness for Melanoma-Prone Families with and without Pathogenic Germline Variants of
    Sargen MR; Pfeiffer RM; Elder DE; Yang XR; Goldstein AM; Tucker MA
    Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):676-681. PubMed ID: 33811164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
    Sargen MR; Calista D; Elder DE; Massi D; Chu EY; Potrony M; Pfeiffer RM; Carrera C; Aguilera P; Alos L; Puig S; Elenitsas R; Yang XR; Tucker MA; Landi MT; Goldstein AM
    J Am Acad Dermatol; 2020 Sep; 83(3):860-869. PubMed ID: 32283231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma.
    Puig S; Potrony M; Cuellar F; Puig-Butille JA; Carrera C; Aguilera P; Nagore E; Garcia-Casado Z; Requena C; Kumar R; Landman G; Costa Soares de Sá B; Gargantini Rezze G; Facure L; de Avila AL; Achatz MI; Carraro DM; Duprat Neto JP; Grazziotin TC; Bonamigo RR; Rey MC; Balestrini C; Morales E; Molgo M; Bakos RM; Ashton-Prolla P; Giugliani R; Larre Borges A; Barquet V; Pérez J; Martínez M; Cabo H; Cohen Sabban E; Latorre C; Carlos-Ortega B; Salas-Alanis JC; Gonzalez R; Olazaran Z; Malvehy J; Badenas C
    Genet Med; 2016 Jul; 18(7):727-36. PubMed ID: 26681309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
    Nielsen K; Harbst K; Måsbäck A; Jönsson G; Borg A; Olsson H; Ingvar C
    Melanoma Res; 2010 Aug; 20(4):266-72. PubMed ID: 20526219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families.
    Taylor NJ; Handorf EA; Mitra N; Avril MF; Azizi E; Bergman W; Bianchi-Scarrà G; Bishop DT; Bressac-de Paillerets B; Calista D; Cannon-Albright LA; Cuellar F; Cust AE; Demenais F; Elder DE; Friedman E; Gerdes AM; Ghiorzo P; Goldstein AM; Grazziotin TC; Hansson J; Hayward NK; Hocevar M; Höiom V; Holland EA; Ingvar C; Landi MT; Landman G; Larre-Borges A; Leachman SA; Mann GJ; Nagore E; Olsson H; Palmer J; Perić B; Pjanova D; Puig S; Schmid H; van der Stoep N; Tucker MA; Wadt KAW; Whitaker L; Yang XR; Newton Bishop JA; Gruis NA; Kanetsky PA;
    J Invest Dermatol; 2016 May; 136(5):1066-1069. PubMed ID: 26827760
    [No Abstract]   [Full Text] [Related]  

  • 19. CDKN2A mutations in multiple primary melanomas.
    Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ
    N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters.
    Karagianni F; Njauw CN; Kypreou KP; Stergiopoulou A; Plaka M; Polydorou D; Chasapi V; Pappas L; Stratigos IA; Champsas G; Panagiotou P; Gogas H; Evangelou E; Tsao H; Stratigos AJ; Stefanaki I
    Acta Derm Venereol; 2018 Oct; 98(9):862-866. PubMed ID: 29774366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.